EWP
ALNY icon

Elevation Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Elevation Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.65K Buy
+31
New +$7.89K ﹤0.01% 987
2026
Q1 		– Sell
-6
Closed -$2.39K – 1080
2025
Q4 		$2.39K Buy
+6
New +$2.65K ﹤0.01% 765

Other funds holding ALNY

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
BFS
Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return

Elevation Wealth Partners's ALNY Position: Q3 2026 in Review

Elevation Wealth Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 31 shares worth $7.65K. The stake represents ﹤0.01% of the portfolio and ranks #987 among its holdings. This is a return to the name: Elevation Wealth Partners previously reported a position in ALNY as recently as Q4 2025.

Elevation Wealth Partners first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Elevation Wealth Partners held 31 shares of Alnylam Pharmaceuticals worth $7.65K as of Q3 2026.
  • Alnylam Pharmaceuticals was a new Elevation Wealth Partners position in Q3 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #987 holding.
  • Elevation Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.